HC Wainwright & Co. Maintains Buy on Pacira BioSciences, Lowers Price Target to $57
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Oren Livnat maintains a 'Buy' rating on Pacira BioSciences (NASDAQ:PCRX) but lowers the price target from $63 to $57.
November 06, 2023 | 11:33 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Despite a lowered price target, HC Wainwright & Co. maintains a 'Buy' rating on Pacira BioSciences, indicating continued confidence in the company's potential.
The lowered price target might initially cause some negative sentiment among investors. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company, which could balance out the initial negative impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100